Rodino-Klapac Louise 4

What Happened

• Louise Rodino-Klapac, President of R&D and Technical Operations at Sarepta Therapeutics (SRPT), was credited with 1,875 shares as a derivative award (PSUs) on Feb 25, 2026. The filing lists this as an award/grant (code A); no purchase price or cash value is reported.
• These are performance stock units (PSUs) earned under a PSU award granted March 1, 2024. The earned PSUs are scheduled to vest on March 1, 2026, contingent on the Reporting Person continuing to provide service through that date.

Key Details

• Transaction date: 2026-02-25; Form 4 filed: 2026-02-27 (appears timely — within the usual 2-business-day reporting window).
• Transaction type/code: A — Award/Grant (derivative security: PSUs); Quantity: 1,875 shares; Price: N/A (PSUs, not a cash purchase).
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: F1 — The 1,875 shares represent PSUs earned based on the Compensation Committee’s determination of milestone achievement under the March 1, 2024 award; vesting on March 1, 2026 is subject to continued service.
• No sale or cash proceeds reported; these units convert to common shares only upon vesting per award terms.

Context

• PSUs are compensation tied to performance and service, not an open-market purchase or sale; they don’t directly signal immediate insider buying or selling activity. Earning PSUs indicates the company met certain performance milestones per the compensation committee, but it is a compensation outcome rather than a trading decision.